QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brahm, N. C Articles by Brown, R. C Search for Related Content PubMed PubMed Citation Articles by Brahm, N. C Articles by Brown, R. C

Buspirone for Autistic Disorder in a Woman with an Intellectual Disability

Clinical Associate Professor, Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Tulsa, OK

Gary A Fast, MD

Consultant Psychiatrist, Outpatient Psychiatry, Wichita, KS

Robert C Brown, MD

at time of writing, Medical Director, Oklahoma Department of Human Services/DDSD and Adjunct Clinical Associate Professor, Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma; now, Consultant, Developmental Pediatrics, Oklahoma City, OK

Reprints: Dr. Brahm, Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, 4502 E. 41st St., 2H17, Tulsa, OK 74135, fax 918/660-3009, nancy-brahm{at}ouhsc.edu

OBJECTIVE: To describe a case of an intellectually disabled patient who was diagnosed with autistic disorder (AD) and responded positively to buspirone, demonstrated by a reduction in target behaviors of self-injury, property destruction, and physical aggression.

CASE SUMMARY: A 33-year-old, white, nonverbal, profoundly intellectually impaired woman (IQ <20-25), residing in a state-run facility, exhibited worsening aggressive behaviors associated with AD. These behaviors were characterized by a history of self-injurious behavior (eg, slapping and scratching herself); property destruction, including breaking windows; and head butting of staff and peers. Additional diagnoses included a seizure disorder, hyperprolactinemia, and osteoporosis. At the time of admission, her drug regimen included 3 atypical antipsychotic agents: risperidone, clozapine, and aripiprazole. Antipsychotic agents have been reported to lower the seizure threshold, and elevated prolactin levels have been associated with risperidone use. Aripiprazole and clozapine were discontinued on admission, and risperidone was discontinued one month later following increased behavioral deterioration. Buspirone was considered an appropriate replacement medication, as it has not been associated with elevated prolactin levels or a lowered seizure threshold, and was initiated at 15 mg/day. Significant reductions in aggression were noted following titration to a total daily dose of 90 mg.

DISCUSSION: Buspirone is approved for treatment of generalized anxiety disorder in adults. Dopaminergic agonist/antagonist actions have been reported with use of higher doses. These receptor effects have been beneficial for aggressive behaviors in the AD population that were exhibited by our patient, but effectiveness for aggression in the intellectually disabled population is uncertain. In our patient, problematic behaviors associated with AD responded positively to buspirone.

CONCLUSIONS: The reduction in target aggressive behaviors achieved with buspirone therapy allowed other treatment interventions to proceed more effectively in our patient. Clinicians may wish to consider use of buspirone in patients with AD who do not respond to or have risk factors for use of other therapy.

Key Words: autism, buspirone, developmentally disabled, intellectual disability

Published Online, December 4, 2007. www.theannals.com, DOI 10.1345/aph.1K427